Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2021 Financial Results
Ovid executing on its strategy to build a leading epilepsy pipeline OV329 expected to enter…
Ovid executing on its strategy to build a leading epilepsy pipeline OV329 expected to enter…
SEATTLE and VANCOUVER, British Columbia, March 15, 2022 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc….
Conference Provides First Exposure of EU and UK AD Experts to INmune Bio’s Approach of…
NCI achieves the enrollment objective of thirty patients in the checkpoint inhibitor refractory arm of…
ROCKVILLE, Md., March 15, 2022 (GLOBE NEWSWIRE) — OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the…
CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology…
SAN DIEGO, March 15, 2022 (GLOBE NEWSWIRE) — Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated…
LEXINGTON, Mass., March 15, 2022 (GLOBE NEWSWIRE) — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the…
Broadened strategic focus and expanded pipeline in immunology and inflammation following acquisition of rights to…
TORONTO, March 15, 2022 (GLOBE NEWSWIRE) — Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:…
– Toripalimab plus chemotherapy met both primary endpoint of progression free survival and prespecified secondary…
GUANGZHOU, China, March 15, 2022 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the…
REHOVOT, Israel, March 15, 2022 (GLOBE NEWSWIRE) — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a…
Revenues Grew 40% for the Fourth Quarter and 42% for Full Year 20212022 Guidance Reaffirmed…
Data readouts from multiple clinical trials expected during the next 6 to 12 months Strong…
DUBLIN, Ireland and FORT WASHINGTON, Pa., March 15, 2022 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc…
On track for top-line data in April 2022 WARRINGTON, Pa., March 15, 2022 (GLOBE NEWSWIRE)…
On track to submit IND application for ENTR-601-44 targeting Duchenne muscular dystrophy in 2H 2022…
Completed enrollment in Phase 2b sickle cell disease and beta-thalassemia trials with tovinontrine (IMR-687); expect…
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG,…